Referred to the House Committee on Energy and Commerce.
This bill directs the Secretary of Health and Human Services, with Commerce, CMS technology council, and the FDA Commissioner, to run a program coordinating U.S.-Israel collaboration on developing and delivering health care products and services. Program elements include joint R&D, start-up and innovation support, regulatory harmonization and IP protections, telemedicine and data-sharing frameworks, biological product manufacturing and workforce training, and disease-prevention cooperation.
Left worries IP/commercial focus could limit affordable access
Relative to its intended legislative type, this bill establishes a substantive federal program with a clear purpose and enumerated components and provides a modest multi-year authorization; however, it remains high-level and would require additional implementation detail, legal authority specification, and accountability mechanisms to operationalize the program effectively.
This bill directs the Secretary of Health and Human Services, with Commerce, CMS technology council, and the FDA Commissioner, to run a program coordinating U.S.-Israel collaboration on developing and delivering health care products and services.
Program elements include joint R&D, start-up and innovation support, regulatory harmonization and IP protections, telemedicine and data-sharing frameworks, biological product manufacturing and workforce training, and disease-prevention cooperation.
The Secretary may establish a U.S.-Israel Health Care Collaboration Center, must begin implementation within six months, and is authorized $8 million annually for FY2026–2030.
Limited cost, technical and pro-innovation content, and targeted scope increase plausibility; funding dependency and Israel-specific politics create uncertainty.
Relative to its intended legislative type, this bill establishes a substantive federal program with a clear purpose and enumerated components and provides a modest multi-year authorization; however, it remains high-level and would require additional implementation detail, legal authority specification, and accountability mechanisms to operationalize the program effectively.
Left worries IP/commercial focus could limit affordable access
These are examples from the analysis, not a ranked list of the most-affected groups.
Left worries IP/commercial focus could limit affordable access
Generally supportive of international collaboration to advance public health and innovation, with reservations about access and equity.
Likely to welcome funding for manufacturing, workforce training, and infectious disease cooperation.
Concerned that strong IP and commercialization language could limit affordable access to new treatments.
Supportive but pragmatic: sees economic and public-health upside and modest cost.
Values technology transfer, supply-chain resilience, and improved regulatory cooperation.
Wants measurable goals, oversight, and clear timelines to avoid waste or mission creep.
Cautiously favorable toward industry-led innovation, U.S. manufacturing, and stronger biotech ties with an allied partner.
Wary of expanding federal programs and potential security or intellectual property risks from sharing data.
Likely to demand protections that prioritize American firms, jobs, and national-security vetting.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Limited cost, technical and pro-innovation content, and targeted scope increase plausibility; funding dependency and Israel-specific politics create uncertainty.
The bill has not accumulated any surfaced votes yet.
Left worries IP/commercial focus could limit affordable access
Limited cost, technical and pro-innovation content, and targeted scope increase plausibility; funding dependency and Israel-specific politi…
Relative to its intended legislative type, this bill establishes a substantive federal program with a clear purpose and enumerated components and provides a modest multi-year authorization; however, it remains high-leve…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.